Back to today’s briefing

Story perspectives

Pfizer and Valneva Pursue Lyme Vaccine Approval Despite Setback

3/25/2026

37 7 Full Breakdown

Summary

Story summary

Pfizer Inc. and Valneva SE plan to seek regulatory approval for the Lyme disease vaccine PF-07307405 despite missing the primary efficacy goal in Phase 3.
The Phase 3 trial showed over 70% efficacy but did not meet the statistical threshold due to fewer-than-expected cases.
Valneva SE's stock dropped significantly following the announcement, and Pfizer Inc.'s shares remained stable.

1 of 1

Story summary

Pfizer Inc. and Valneva SE plan to seek regulatory approval for the Lyme disease vaccine PF-07307405 despite missing the primary efficacy goal in Phase 3.
The Phase 3 trial showed over 70% efficacy but did not meet the statistical threshold due to fewer-than-expected cases.
Valneva SE's stock dropped significantly following the announcement, and Pfizer Inc.'s shares remained stable.